Nivolumab Plus Ipilimumab Offers Improved Survival Outcomes in Certain Metastatic CRC Patients

Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high response rates and improved survival outcomes compared with those who received nivolumab alone.

Source: CancerNetwork - January 23, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer News Source Type: news